Serologic cross-reactivity, a hallmark of orthopoxvirus (OPXV) infection, makes species-specific diagnosis of infection difficult. In this study, we used a variola virus proteome microarray to characterize and differentiate antibody responses to nonvaccinia OPXV infections from smallpox vaccination. The profile of 2 case patients infected with newly discovered OPXV, Akhmeta virus, exhibited antibody responses of greater intensity and broader recognition of viral proteins and includes the B21/22 family glycoproteins not encoded by vaccinia virus strains used as vaccines. An additional case of Akhmeta virus, or nonvaccinia OPXV infection, was identified through community surveillance of individuals with no or uncertain history of vaccination and no recent infection. The results demonstrate the utility of microarrays for high-resolution mapping of antibody response to determine the nature of OPXV exposure.
Orthopoxviruses (OPXVs) make up a genus of large double-stranded DNA viruses that can infect humans and include variola virus (VARV; the causative agent of smallpox) and vaccinia virus (VACV; used in modern vaccines for smallpox). Antibodies to VACV are highly cross-reactive between OPXV species and confer protection against other OPXV infections [1] . Because these antibodies can last for decades, there are individuals, particularly among those >40 years of age, who still have antibodies from the smallpox eradication campaign [2] . However, the protective efficacy of long-lived antibodies years later is uncertain [3] , and the cessation of worldwide vaccination subsequent to the eradication of smallpox has left a large proportion of the current population susceptible to OPXV infections. The discontinuation of vaccination and waning immunity may be contributing to the rise in cases of zoonotic OPXV infections [4] .
Human OPXV infections occur worldwide: cowpox virus (CPXV) circulates in Europe and Western Asia, VACV variants in Brazil and Colombia, buffalopox virus in India and Bangladesh, and monkeypox virus (MPXV) in Central and Western Africa, and Akhmeta virus (AKMV) has been discovered in the country of Georgia [4] [5] [6] [7] . Species-specific diagnosis of OPXV infection requires collection of acute lesion samples for polymerase chain reaction-based diagnostics; however, infections with VACV, CPXV, and AKMV are usually self-limiting, so medical care and patient samples are often not available. Infections of MPXV typically occur in remote locations, and investigators often arrive late in the outbreak, resulting in a large number of suspected cases but no clear ability to determine the extent of the outbreak.
A serologic assay that could identify and differentiate natural infection from prior vaccination would be useful in determining the true scope and burden of OPXV outbreaks. The presence of anti-OPXV immunoglobulin (Ig) M antibodies is indicative of recent infection; however, the IgM response is observed only during primary infection or vaccination or by exposure to antigenically distinct OPXVs and lasts only 1-6 months after exposure [8] . Laboratory methods to serologically differentiate infections by OPXV species exist but are time consuming, and many require adsorption of cross-reactive antibodies and careful interpretation of findings, because incomplete adsorption can confound results [9, 10] . Genome analysis has shown that though most OPXV viral proteins have >95% homology, some differences are present and some proteins are completely absent from or unique to particular species. For example, all known OPXVs except VACV encode a large glycoprotein (B22 in VARV and B21 in MPXV). B21/22 peptide-based enzyme-linked immunosorbent assays (ELISAs) have been used to attempt specific detection of MPXV [11] , but utility for other OPXV infection may be limited.
In 2013, 2 cases were reported of a poxvirus like infection in cattle herders who had never been vaccinated against smallpox [7] .
In these individuals, cutaneous lesions developed on their hands after they had handled ill cows. Genetic sequencing of lesion samples and phylogenetic analysis indicated that the virus was a novel OPXV, now named AKMV, and not a CPXV as originally suspected. Subsequent investigation revealed no additional human cases of AKMV infection (based on IgM response) among the close contacts of the patients or others with potential occupational exposure to the affected herd, although some were positive for anti-OPXV IgG but reported no history of vaccination.
As part of a retrospective study, and to explore the immune profile of confirmed cases, we undertook analysis using a newly generated proteome microarray to investigate the antibody reactivity against individual VARV proteins from these index case patients, as well as naive and IgG-positive individuals, with or without a history of vaccination. Here, we confirm an additional case of infection with a non-VACV OPXV that was previously unrecognized based on (1) specific reactivity to the B22/B21 poxvirus proteins and (2) overall reactivity profile. We also compare serologic reactivity between cattle with suspected infection in the index herd and those without evidence of infection from nearby and distant farms.
METHODS

Human and Cattle Sample Collection and Use
Collection of serosurveillance samples were described elsewhere [7] . Briefly, 37 individuals including the 2 index case patients and additional interviewees from the region, provided serum used herein to aid in identification of AKMV infection. Specimens were collected approximately 3 months after symptom onset for the 2 patients with confirmed AKMV. In addition, 11 cattle from the index herd, including 4 with a history of poxlike lesions, and 24 cattle from other herds with no history of illness were sampled. Routine smallpox vaccination was discontinued in Georgia in 1981; individuals born after this date would typically be OPXV naive [7] . Humans were classified as "naive" or "vaccinated" based on age, vaccination history, and ELISA results. Possible cases of AKMV infection were in individuals with no vaccination history but positive responses IgG ELISA responses. Samples were collected in cooperation with the National Center for Disease Control and Public Health and the Ministry of Agriculture of Georgia, after verbal consent was obtained from participants. Investigation procedures were reviewed by the Centers for Disease Control and Prevention (CDC), Atlanta and determined to be nonresearch (RD-083013NV), relating to outbreak investigation and retrospective case identification. Human samples tested are summarized in Table 1 .
ELISA Procedures
To determine the presence of anti-OPXV antibodies, ELISAs were performed as previously described [8, 12] . Briefly, the human IgG ELISA used microtiter plates (Immulon II) coated with purified VACV (1.2 × 10 5 plaque-forming units per well), which were inactivated with 10% buffered formalin for 15 minutes. The plates were blocked for 30 minutes at room temperature, washed with phosphate-buffered saline with 0.05 % Tween-20 (PBST), incubated with 1:100 diluted serum for 1 hour at 37°C, washed with PBST, incubated with secondary antibody 1:2000 diluted goat anti-human IgG-horseradish peroxidase (Kirkegaard & Perry Laboratories [KPL]) for 1 hour at 37°C, and finally washed with PBST. Tetramethylbenzidine (TMB) substrate (KPL) was added, and the reaction was developed for 5-15 minutes before optical densities (ODs) were read at 450 nm on an EnSpire Reader (ThermoFisher/PerkinElmer).
Cutoff values (COVs) were determined based on the mean OD plus 3 standard deviations for 5 negative control serum samples. Resulting OD minus COV (OD-COV) values determined whether a sample was OPXV positive (OD-COV, >0.0) or negative (OD-COV, <0.0). The IgM ELISA used buffers, incubation times, and cutoff calculations similar to those used for the IgG ELISA but substituted appropriate reagents. Briefly, goat anti-human IgM (KPL) was coated on the microtiter plate overnight and blocked, followed by these steps: human serum at 1:50, wash, purified VACV (6 × 10 5 plaque-forming units per well), formalin inactivation, wash, anti-OPXV hyperimmune mouse ascites fluid (CDC), wash, goat anti-mouse horseradish peroxidase (BioRad), TMB substrate, color development, stop solution, OD measurement, and OD-COV calculation for identification of positive reactions. ELISA for cattle serum samples used microtiter plates (Immulon II) coated overnight with crude VACV-or AKMV (GA088 strain)-infected cell lysate and control uninfected BSC-40 cell lysate, which were then inactivated with 10 % buffered formalin for 15 minutes at room temperature, blocked for 30 minutes, washed with PBST, incubated with 1:100 diluted cattle serum for 1 hour at 37 °C, washed with PBST, incubated with 1:30 000 diluted ImmunoPure A/G conjugate (Pierce) for 1 hour at 37 °C, and washed with PBST. TMB substrate was then added, and the plate developed for 5-15 minutes before OD reading at 450 nm. ELISA-positive human and rabbit serum samples, and negative cow serum samples, were used as assay controls. The control uninfected lysate-only portion of the plate was used to generate a COV for each plate by averaging cell lysate results and adding 2 standard deviations. Specimens were considered positive if the OD value was above the COV.
Microarray Generation and Screening
The VARV protein microarray was fabricated as described elsewhere [13] and will be described in detail elsewhere (M. B. T. et al, in preparation). Briefly, individual open reading frames for VARV Bangladesh Banu were amplified and cloned into T7 expression vectors with 6X-histidine tags (ThermoFisher/Invitrogen). Proteins were expressed using Escherichia coli-based cell-free coupled transcription/translation reactions (RTS 100 kits; 5 Prime) and printed without purification on nitrocellulose-coated slides (Whatman). MPXV B21 (orthologue of VARV B22) was also included in the array. Owing to their large size, B22 and B21 were expressed as protein fragments of 400-500 amino acids. No-DNA control spots containing the reaction mixture but no template DNA were included to correct for background binding to E. coli proteins found in the transcription-translation mixture.
Positive responses were defined as >2000 relative fluorescence units (RFUs), based on a cutoff of <1% false-positives in naive samples. A cutoff of 2000 RFUs was used for cattle samples and validated by querying proteins known to not produce a response after OPXV vaccination or natural infection (data not shown); a total of 137 proteins were selected, and 2000 RFUs had <1% false positives. Where available, the VACV Copenhagen strain names are used to refer to VARV homologous proteins. The B22 family of proteins is not present in VACV Copenhagen and is designated based on VARV nomenclature.
Human and cattle serum samples were probed on the arrays at 1:100 dilution in protein array blocking buffer (Antigen Discovery Inc [ADI]) plus 20% E. coli lysate to block antibodies reactive toward E. coli proteins. The remaining steps were carried out in blocking buffer with 1% E. coli lysate. Vaccinia immune globulin was used as a control for intra-array comparison and was probed at 1:500 dilution. For human serum samples and vaccinia immune globulin, ADI secondary anti-human IgG-biotin conjugate at 1:1000 was used, followed by streptavidin-fluorophore. Cattle antibodies were visualized using protein G-biotin (Pierce) at 1:200, followed by ADI streptavidin-fluorophore. Microarrays were scanned using a Gene Pix 4100A scanner with laser settings at 100% and a photomultiplier tube (PMT) gain of 350, and images were analyzed with Genepix Pro 5.0 software (Molecular Devices). Spot intensity was calculated as the median value minus local background. A secondary correction for background binding to E. coli proteins was done by subtracting an average of the "no DNA" spots from the background-corrected spot value.
RESULTS
Human Serum Reactivity to VARV Proteins
Naive individuals (n = 7) ranged from 14 to 38 years old, were deemed negative by absence of any recorded smallpox vaccination or scar, and were negative by standard anti-OPXV IgG and IgM ELISA (Table 1 and Figure 1, top) . Reactivity of serum samples from naive individuals by microarray was minimal, with few instances of reactivity to the VARV homologues above a cutoff of 2000 RFUs ( Figure 1, bottom) ; sporadic reactivity observed was to proteins that did not correlate with known immunodominant (ID) hierarchy after vaccination or infection [14, 15] .
By comparison, serum samples from the 2 case patients with confirmed AKMV infection had high positive ELISA IgG and IgM responses, with the latter indicating a recent OPXV infection. These samples had broad reactivity to VARV proteins by microarray, including VARV B22 and MPXV B21 fragments, as well as other ID proteins: structural proteins associated with crescent formation, D13; core formation and associated proteins, A10, I1, A12, A32, I3, A6, and H5; mature virion membrane proteins H3, D8, A27, and I2; extracellular virion membrane proteins, F13, A56, B5, and A36; and other evasion, virulence, and host cell-associated proteins, C23 and its gene duplicate B29, G5.5, E3, A11, C6, A38, and A6. Reactivity against VARV B22 and/or MPXV B21 demonstrated infection with a non-VACV OPXV. As confirmed by virus isolation and sequencing from index case patients, the results here demonstrate a broadly reactive antibody profile, including B22/B21, after AKMV infection.
We next examined antibody responses from vaccinees (n = 11) (Figure 2 ). These individuals, aged 42-88 years, had a self-reported history of vaccination and were all born before the cessation of smallpox vaccination in the country of Georgia; their serums were probed by ELISA and microarray. Vaccinee serum were negative by IgM ELISA but had IgG ELISA OD-COVs ranging from 0.13 to 1.49 (Table 1 and Figure 2 
, top).
Responses by microarray showed a strong response to a limited set of proteins (Figure 2, bottom) . Interestingly, there was some low-level antibody response against MPXV B21; this could be indicative of non-VACV OPXV infection or due to some low-level cross-reactivity to this protein. VARV homologues of D13 and A10 were recognized by most vaccines, whereas more than half reacted with I1, H3, and F13, and >25% reacted with D8, A27 and A36. Compared with serum samples from patient with confirmed AKMV infection, vaccinees generated a narrow antibody response against ID proteins.
Finally, serum samples from 6 individuals identified as possible AKMV case patients were probed on the microarray; they had no history of vaccination and had negative IgM but positive IgG, ELISA results. Serum samples from 4 individuals with low IgG ELISA OD-COV values (0.01-0.12) did not demonstrate significant antibody response by microarray. An additional sample, sample 883, had a low IgG ELISA value and demonstrated antibody reactivity against only D13 and I1 proteins but had no responses against other ID proteins. Interestingly, sample 900 exhibited strong and broad responses against more than 30 VARV proteins, similar to the 2 confirmed AKMV cases. Most importantly, antibodies from this individual reacted with B22 and B21 protein fragments, consistent with non-VACV OPXV infection, possibly AKMV.
Cattle Serum Reactivity to OPXV Proteins
Serum samples were collected from 5 herds: 1 co-owned by the confirmed human AKMV case patients (herd A), 2 from nearby farms (herds B and C), and 2 from distant farms (herds D and E) distally located. Most animals in herd A, including suspected cases in cattle with a history of lesions, were positive by VACV Western Reserve or AKMV GA088 strain antigen ELISAs (Figure 3, top) . Reactivity by Western blot showed that, in general, animals from herd A reacted with 3-4 bands that correlate in size with known OPXV reactive proteins (Supplementary Figure S1) . Microarray results (Figure 3, bottom) indicate reactivity to D13 and A10 proteins in most of herd A cattle, including the 4 with acute disease and suspected infection. No responses from any group were seen to B22/B21 protein fragments. Cattle from nearby (herds B and C) and distant (herds D and E) farms showed some reactivity to D13 but not A10. As seen in humans, sporadic low-level reactivity was seen in both naive and acutely infected animals but did not seem specific for OPXV infection.
DISCUSSION
In 2013, scientists from the US CDC and the Georgian National Center for Disease Control and Public Health obtained samples from individuals suspected of having cowpox infection. Based on whole-genome sequencing and phylogenetic analysis the virus was determined to be a novel OPXV, now known as AKMV. In addition to acute infection samples used for direct virus isolation, approximately 3 months after illness first occurred in the index case patients, a serologic surveillance investigation was undertaken to identify additional cases of AKMV infection [7] . Analysis by IgG or IgM ELISA only verified the presence of antibodies to OPXV but could not differentiate which OPXV was the causative agent, nor could it differentiate previous vaccination from natural infection. Using a VARV proteome microarray, we were able to demonstrate antibody responses against individual VARV proteins from the 2 confirmed AKMV cases. The antibody response to AKMV infection was broad compared with a limited reaction observed after vaccination. Of particular interest, antibody response was observed against B22/B21 orthologues, which are large surface-expressed glycoproteins encoded by only non-VACV OPXVs. B22 family proteins are absent in all sequenced VACV to date (data not shown) and have been shown to be a target of humoral immune Vaccinated Individuals Potential AKMV Cases responses in both small animal models and human cases of MPXV infection [14, 16] . Thus, using this proteome microarray, we were able to further detail antibody responses to AKMV infection among a limited number of confirmed cases. Microarray analysis of all naive samples (classified based on IgG-negative ELISA, age, and no history of smallpox vaccination) did not show reactivity against known ID proteins. Samples from vaccinated individuals exhibited antibody responses to limited but previously demonstrated major protein targets (about 8 OPXV proteins) [14, 15] , corroborating ELISA results and vaccination history. Several serum samples from vaccinees exhibited low-level reactivity to the B21 protein, including sample 899, which had fluorescence of 4751 RFUs. Interestingly, this serum sample also had the broadest response in the vaccinee group. Antibody responses are known to decline 1-2 years beyond infection and reduced levels of antibody are known to limit assay sensitivity [11] ; thus, we may be observing some distant past non-VACV infection. Alternatively, the level of responses to B21 were well below that seen in the serum samples from patients with confirmed AKMV and may be indicative of some low-level cross-reactivity and thus caution interpretation of these low-level responses.
It may also be necessary in the future to define different COVs for individual proteins to improve identification of true reactivity. Serum antibody responses from the 6 potential AKMV infection cases produced several different profiles. Four of the 6 potential cases, including samples 913, 895, 906 and 896, appeared negative with an absence of responses to known ID proteins [15] . Thus, the weak-IgG ELISA-positive results observed for these cases might be due to higher background or individual variations in antibody responses, and they illustrate the need careful evaluation of low-IgG responses and encourage additional validation using controls from Georgia. Of 2 remaining possible AKMV cases, sample 883 had strong reactivity to proteins D13 and I1 but otherwise did not respond to typical OPXV proteins seen in vaccinees. Reviewing the epidemiological data, we observed that this individual was from a nearby town relative to confirmed cases and had worked with cattle. Although these findings were suspicious, given the absence of reactivity to B22/B21 and broadly to OPXV proteins, evidence does not support recent exposure to AKMV or to any natural infection by non-VACV OPXV.
One major finding from this retrospective study was identification of an individual not previously noted to have a confirmed AKMV infection. Sample 900 showed strong antibody responses to >30 proteins, including both B22 and B21 fragments; this reactivity was similar to that in the 2 previously confirmed AKMV cases. This individual was born before the cessation of routine smallpox vaccination in Georgia, did not recollect smallpox vaccination or note a scar indicating vaccination, and did not recall recent infection with lesions before the investigation period. This information was corroborated by negative findings of anti-VACV IgM ELISA, suggesting that the individual had not been recently infected. Epidemiological findings showed that this individual was a family member of one of the original confirmed case patients and had tended to the index herd (see Vora et al [7, supplementary appendix]). We conclude that this OPXV response was probably due to AKMV or similar non-VACV OPXV infection, based on the broad antibody profile and reactivity to the B22/B21 orthologues. Cattle serum reactivity in OPXV assays correlated with epidemiological findings and those in human samples. The strongest antibody responses were from animals in herd A, in which lesions had been reported. Serum samples from these cattle were generally OPXV positive by ELISA and reacted with multiple bands by Western blot (Supplementary Figure S1 ). This contrast with other herds where limited or no banding was seen. Reactivity by microarray, although reduced relative to human responses, was found against 2 major ID proteins, D13 and A10. Interestingly, there was no reactivity to the B22/B21 homologues, including cattle identified with lesions on the animal's teats. Thus, this microarray analysis method, though valuable for examining responses in humans, requires additional testing in animals to assess the utility of these responses for surveillance, serologic surveys, or for diagnostic testing of cattle after convalescence.
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Separately, it has been noted that systemic OPXV infection, as occurs during MPXV infection, produces antibody response that is more intense and reactive to a much broader set of OPXV proteins than after vaccination [14, 17] . Benhnia et al observed that redundancy of neutralizing antibody responses were a key feature of smallpox vaccination [18] ; antibodies to H3 were depleted, yet neutralization capacity of serum remained. It has also been noted that antibody-based immunity after smallpox vaccination, while durable, did not always protect from VARV infection [16] . One explanation may be related to the type of antibody response generated. Smallpox vaccination using Dryvax in adults was recently shown to produce a humoral response that declined more rapidly than childhood vaccination [19] . Keckler et al [20] also previously observed in a prairie dog model that vaccination with attenuated vaccines, while preventing death, does not always protect from morbid effects during MPXV challenge. Given consistency in specific ID responses after vaccination, it would be interesting to see whether the relationship between broad reactivity after AKMV and other systemically spread virus infection correlates with greater long-term protection.
In conclusion, the advantages offered by proteome microarray include identification of non-VACV infection and potential differentiation of vaccination from natural infection based on reactivity profile against a broad range of targets, including the B22/B21 protein, and confirmation of previous results for samples exhibiting positive ELISAs with low or equivocal IgG. Thus, microarray technology could offer improved detection of OPXV disease burden in serosurveillance samples by dissecting unique antibody targeting after OPXV vaccination or infection and could potentially provide clarification for samples that might otherwise have artificially high background by ELISA.
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